Ticagrelor monotherapy in patients at high bleeding risk undergoing percutaneous coronary intervention: TWILIGHT-HBR

Escaned, Javier; Cao, Davide; Baber, Usman; Nicolas, Johny; Sartori, Samantha; Zhang, Zhongjie; Dangas, George; J. Angiolillo, Dominick; Briguori, Carlo; J. Cohen, David; Collier, Timothy; Dudek, Dariusz; Gibson, Michael; Gil, Robert; Huber, Kurt; Kaul, Upendra; Kornowski, Ran; W. Krucoff, Mitchell; Kunadian, Vijay; R. Mehta, Shamir; J. Moliterno, David; Magnus Ohman, E.; G. Oldroyd, Keith; Sardella, Gennaro; K. Sharma, Samin; Shlofmitz, Richard; Weisz, Giora; Witzenbichler, Bernhard; Pocock, Stuart; Mehran, Roxana

doi:10.1093/eurheartj/ehab702

Public

Ticagrelor monotherapy in patients at high bleeding risk undergoing percutaneous coronary intervention: TWILIGHT-HBR

Published in European Heart Journal • Sep 15, 2021

Authors:

Javier Escaned

Davide Cao

Usman Baber

Abstract

AIMS: Patients at high bleeding risk (HBR) represent a prevalent subgroup among those undergoing percutaneous coronary intervention (PCI). Early aspirin discontinuation after a short course of dual antiplatelet therapy (DAPT) has emerged as a bleeding avoidance strategy. The aim of this study was to...

Subject

Medicine

Ticagrelor

Percutaneous coronary intervention

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!